Overview

Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC

Status:
Recruiting
Trial end date:
2024-10-30
Target enrollment:
Participant gender:
Summary
To investigate efficacy and toxicity of regorafenib after treatment with atezolizumab and bevacizumab combination
Phase:
Phase 2
Details
Lead Sponsor:
CHA University
Collaborator:
Bayer